Materias dentro de su búsqueda.
Mostrando 3,501 - 3,520 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 3501
    “…Randomized clinical trials that compared the efficacy and safety of sorafenib plus chemotherapy in patients with HER2-negative advanced breast cancer with placebo plus chemotherapy were eligible. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis
  2. 3502
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells
  3. 3503
    por Maly, Joseph J, Macrae, Erin R
    Publicado 2014
    “…Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
  4. 3504
    “…To the best of our knowledge, the present study is the first to report IAC metastasis due to LMC in human epidermal growth factor receptor 2 (Her2)-positive GC. This study reports a case of an Her2-positive GC patient with LMC including IAC metastasis, who presented with acute sensorineural hearing loss, ipsilateral facial paralysis and vertigo during trastuzumab containing chemotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sudden hearing loss due to internal auditory canal metastasis of Her2-positive gastric cancer: A case report
  5. 3505
    por Tawfeek, A
    Publicado 2014
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P30. The use of HER2 receptors status as a prognostic index for estrogen receptor positive breast cancer patients
  6. 3506
    “…METHODS: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
  7. 3507
    “…ScFv-L-Aff mediated the binding of the hapten to HER2 on SK-BR3 cells and from tissue from the SK-BR3 xenograft; however, scFv-L-Aff did not mediate uptake of the hapten in the SK-BR3 xenografted tumors, presumably due to rapid internalization of the HER2/scFv-L-Aff complex. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Discovery of Hapten-Specific scFv from a Phage Display Library and Applications for HER2-Positive Tumor Imaging
  8. 3508
    “…In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
  9. 3509
    “…Centrosome amplification (CA) amongst particular breast cancer subtypes (Her2+ subtype) is associated with genomic instability and aggressive tumor phenotypes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells
  10. 3510
    Publicado 2014
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients
  11. 3511
    por Yoon, S, Lee, M-Y, Park, B-W, Kim, K-S
    Publicado 2005
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells
  12. 3512
    “…Understanding the signaling differences that distinguish human HER2-amplified (HER2-positive (HER2+)) breast cancers from other breast cancer subtypes may help to identify protein drug targets for the specific treatment of HER2+ breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy
  13. 3513
    “…Of these, 6 cases were HER2 amplified in the primary GC and not amplified in the metastases, while 4 were HER2 not amplified in the primary tumour and amplified in the lymph node metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis
  14. 3514
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Profiling of suppressive immune subsets in metastasis negative and positive sentinel lymph nodes from patients with HER2- breast cancer
  15. 3515
    “…BACKGROUND: Neoadjuvant Chemotherapy (NC) including trastuzumab induces a high rate of pathological Complete Responses (pCR) in patients with locally advanced HER2-overexpressing Breast Cancer (BC), but is penalized by a severe cardiotoxicity when combined with anthracyclines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
  16. 3516
    “…A genetic complementation assay with mutant proteins was combined with biochemical characterization demonstrating that the ATPase activity of HerA, the interaction between HerA and NurA, and the efficient 5′-3′ DNA end resection activity of the HerA-NurA complex are essential for cell viability. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficient 5′-3′ DNA end resection by HerA and NurA is essential for cell viability in the crenarchaeon Sulfolobus islandicus
  17. 3517
    “…CONCLUSION: SDC is a rare tumor and information on association of HER2/neu with survival is useful in further research on this tumor.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up
  18. 3518
    “…HER2-positive breast cancer accounts for 25% of all cases and has a poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors
  19. 3519
    “…BACKGROUND: There is limited effect of tyrosine kinase inhibitors or “naked” antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder cancer and these methods are therefore not routinely used. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides
  20. 3520
    “…HER-2 targeted therapy in breast cancer depends on the reliable assessment of HER-2 expression status but current standard methods are lacking a rigorous quantitative assay. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array
Herramientas de búsqueda: RSS